Vitrolife starts direct sales of fertility media in France

Vitrolife starts direct sales of fertility media in France

Vitrolife takes over marketing and sales of media products within the fertility
area in France. This is line with Vitrolife's strategy to use its own
organization in key markets and gives the company the opportunity to be more
aggressive and increase its market share in the French market.

Since 1998 JCD SAS has been responsible for sales and distribution of
Vitrolife's media products within fertility in France. Vitrolife will now take
over management of marketing and sales in France. Vitrolife already has a branch
office in France, through which instrument products have been sold.

”Vitrolife wishes to thank JCD for the years of successful and dedicated work
that have been put into sales of and customer support for Vitrolife's products
in France. As from May 1, 2008 we begin marketing and distributing the complete
product line direct from Vitrolife. We can then offer our customers a broader
range of products and service by providing both cultivation media and
instruments”, says Nils Sellbom, Director of Sales at Vitrolife.

The consolidation of the sales activities of the former Swemed and Vitrolife
product portfolios, thereby achieving marketing synergies, is a process
Vitrolife has been pursuing worldwide since the acquisition of Swemed, with the
aim of using its own market organization in key markets with a wider product
range.



February 5, 2008
Kungsbacka, Sweden 

Magnus Nilsson
CEO





Queries should be addressed to: 
Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.


________________________________________________________________________________
_________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. The Fertility product area works with
nutrient solutions (media) and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to maintain tissue in optimal
condition outside the body for the required time while waiting for
transplantation. The Stem Cell Cultivation product area works with media and
instruments to enable the use and handling of stem cells for therapeutic
purposes. 
     Vitrolife today has approximately 140 employees and the company's products
are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and
there are subsidiaries outside Gothenburg, Sweden and in Denver, USA. The
Vitrolife share is listed on the OMX Nordic Exchange's Nordic Small Cap list.
________________________________________________________________________________
_________
Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate
identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.